GLP-1 self-optimization claims on TikTok: what the data says

What did @hackinggirly actually say?

She's been on what she calls "Trisiana" (likely tirzepatide) for ten weeks, completed four weeks at what sounds like 10 mg, and is now adding "Serviana" (likely semaglutide) to the mix. Her jab day is Tuesday, and she's shifting it to Wednesday to create spacing between injections. She frames this as careful, slow titration, saying she "wanted to take time" and "titrated slowly and safely." She also mentions she previously used "Greta" (likely a reference to a GLP-1 compound, possibly liraglutide or retatrutide) and switched to tirzepatide. The overall message is that stacking multiple GLP-1 or GLP-1 adjacent compounds is a logical next step when one isn't delivering fast enough results.

To be clear about what she's not doing: she's not prescribing anything to viewers. She says upfront this is not advice. That disclaimer matters, but it doesn't change what the content actually models for a large audience.

Does the science back this up?

No published clinical trial has studied the concurrent use of tirzepatide and semaglutide in humans. These aren't two supplements you layer for synergy. They act on overlapping receptor pathways, and stacking them doesn't have a studied safety profile.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist. Both slow gastric emptying, suppress appetite via GLP-1 pathways, and carry overlapping adverse effect profiles including nausea, vomiting, pancreatitis risk, and potential thyroid C-cell effects in susceptible individuals. Combining them means doubling down on those risks without doubling down on studied benefit. Wilding et al. (2021, NEJM) demonstrated semaglutide's efficacy as a standalone agent. Jastreboff et al. (2022, NEJM) did the same for tirzepatide. Neither study tested combination use, and neither suggested combination use as a logical extension of the findings. Shifting injection days to create "space" between compounds doesn't address receptor-level interaction or cumulative pharmacodynamic overlap.

What did they get wrong (or right)?

Credit where it's due: her emphasis on nutrition, hydration, and resistance training as the foundation is genuinely correct. GLP-1 agents work best alongside lifestyle changes, not instead of them. That part she got right, and it's worth acknowledging.

What she got wrong is more significant. The framing of stacking two GLP-1 pathway drugs as a "cherry on top" dramatically undersells the risk. There's no evidence that adding semaglutide to tirzepatide produces additive weight loss. In fact, because tirzepatide already activates GLP-1 receptors, adding a pure GLP-1 agonist may produce redundant receptor stimulation rather than meaningful additional benefit. The adverse effect overlap, particularly around pancreatitis and gastrointestinal complications, is not trivial. Sarnoff et al. (2023, Pharmacotherapy) noted that GLP-1 agonist combinations lack safety data and that compounded formulations add additional uncertainty around dosing accuracy. Calling this "titrating slowly and safely" misapplies the word safely to an unstudied protocol.

What should you actually know?

If you're on a GLP-1 agent and feel like it's not working fast enough, that's a conversation for your prescriber, not a TikTok stack. Dose escalation within a single proven agent has a studied rationale. Switching agents has some evidence base. Combining them does not.

It's also worth being specific about what these compounds are. The nicknames "Trisiana," "Serviana," and "Greta" used in this video are almost certainly references to compounded peptide formulations, not FDA-approved brand-name drugs. Compounded semaglutide and tirzepatide are not equivalent to Wegovy, Ozempic, Mounjaro, or Zepbound in terms of verified purity, dosing accuracy, or regulatory oversight. The FDA has issued multiple warnings about compounded GLP-1 drugs, including reports of dosing errors leading to hospitalizations. Combining two compounded agents whose actual concentrations may vary batch to batch adds a layer of risk the creator doesn't address at all.

The bottom line: stacking GLP-1 pathway agents is not an established clinical practice, has no human trial support, and carries real overlapping risks. "I've done my research" in this context means personal experimentation, which is not the same thing as clinical evidence.